EMA Consults On Endpoint For Faster Multiple Myeloma Drug Approvals
Executive Summary
There is convincing data available on the use of negative minimal residual disease (MRD) as an intermediate endpoint, as long as the benefit in terms of long-term efficacy can be confirmed.
You may also be interested in...
Pharma Wants Clarity On Use of EMA’s New Myeloma Endpoint
Companies want to know whether the European Medicines Agency's draft guideline on a new endpoint for multiple myeloma studies can be applied across different regulatory procedures.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.